Retatrutide (Lilly's code name LY3437943) is Eli Lilly's first long-acting GLP-1/GIP/Glucagon triple receptor agonist peptide after telpolide, administered subcutaneously once a week. As of July 2026, it had not yet been approved-neither by the FDA nor the EMA. Eli Lilly stated it planned to submit a BLA in the first quarter of 2027, meaning it would likely not be available on the market until late 2027 or later.
Its main functions and physical mechanisms are quite robust: First, it involves a dual metabolic intervention of "increasing supply and reducing expenditure." GLP-1 and GIP receptors are responsible for "reducing expenditure," significantly decreasing calorie intake by delaying gastric emptying and suppressing central appetite, while intelligently promoting insulin secretion; while the GCG receptor is responsible for "increasing supply," acting directly on the liver to promote lipid metabolism and energy expenditure. This mechanism not only helps you eat less but also encourages your body to actively burn more fat, thus perfectly avoiding the metabolic adaptations common in traditional weight-loss drugs (i.e., the body lowers its basal metabolic rate to combat weight loss).
Storage Conditions
Lyophilized powder (research/experimental grade): Store at 2–8℃, protected from light and sealed. It can be stored for approximately 2 years. Nitrogen filling at -20℃ provides better stability. For short-term room temperature transport in the original packaging (≤30℃, protected from light), do not exceed 7 days.
After reconstitution (using sterile water/benzyl alcohol-containing antibacterial water, slowly push along the wall, do not vortex): Refrigerate at 2–8℃, protected from light. Use within 28 days. Do not freeze the reconstituted solution; repeated freeze-thaw cycles will damage the core structure.
The solution should be clear and colorless. Discard any solution that is cloudy, discolored, or contains suspended matter. Write the reconstitution date; do not rely on memory.
Important Notes and Personal Opinions
Currently, any "Retatrutide lyophilized powder/pen" on the market is either from grey market sources or is a research-grade raw material. It is not Eli Lilly's clinical drug, and its purity, sterility, and true sequence are not guaranteed. Eli Lilly has publicly warned that illegal products may contain unknown impurities, dosage mismatches, or may not even be the same product. Do not buy online and prepare it yourself.
Contraindications are similar to those of telpotetide: Personal/family history of MTC, MEN2, type 1 diabetes, history of acute pancreatitis, pregnancy/female breastfeeding, and avoid use in individuals under 18 years of age;
The side effect spectrum remains the same as GLP-1 inhibitors-nausea/vomiting/diarrhea/constipation are concentrated in the two weeks following dose increases, with approximately 11.3% of patients in the 12 mg group discontinuing treatment due to adverse reactions. A new signal emerging in Phase III is dysesthesia (abnormal tingling/numbness), with the highest reported incidence in the 12 mg group reaching 12.5%. Although mostly transient, the mechanism is not fully understood, requiring more caution than with telpotetide;
When used in combination with insulin/sulfonylurea, the latter's dose must be reduced to prevent hypoglycemia; If gallbladder pain, jaundice, or persistent severe abdominal pain radiating to the back (suspected pancreatitis) occurs, immediately discontinue treatment and seek medical attention;
The escalation regimen follows the Phase III protocol: start with 2 mg, increasing by one level every 4 weeks to 4/6/9/12 mg. Do not follow the advice of online influencers who directly use 4 mg or 6 mg. At the beginning, what came out of the fire were all gastrointestinal tracts;
Hot Tags: research experimental peptide retatrutride cas: 2381089-83-2, China research experimental peptide retatrutride cas: 2381089-83-2 manufacturers, suppliers, factory
